• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Ophthalmology

Anti-VEGF therapy for retinopathy of prematurity may be associated with pulmonary hypertension risk

byMolly Munsell
October 19, 2022
in 2 Minute Medicine, Ophthalmology, Pediatrics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In a large cohort of infants treated for retinopathy of prematurity, those who received anti-VEGF therapy were more likely to be later treated for pulmonary hypertension (PH) than matched infants who received laser therapy.

2. After adjustment for hospital and year, the association between anti-VEGF therapy and PH was not statistically significant.

Evidence Rating Level: 2 (Good)

Study Rundown: Retinopathy of prematurity (ROP) is a common and morbid condition in infants born preterm. Currently, it is most often treated with anti-vascular endothelial growth factor (VEGF) injections, laser photocoagulation, or both. Though anti-VEGF therapy is used in other retinal diseases, its use and risks in the ROP setting are incompletely understood. This multicenter retrospective study aimed to assess whether anti-VEGF therapy was associated with elevated risk of pulmonary hypertension (PH). Of about 1,600 included patients, 56.3% received anti-VEGF therapy. After propensity score matching between 491 patients each treated with anti-VEGF and laser, infants treated with anti-VEGF were 71% more likely to be treated for PH; this difference was narrowly statistically significant. The significance disappeared when adjusted for hospital site and year of treatment, although PH still occurred in a higher proportion of anti-VEGF-treated infants. Notably, anti-VEGF use increased over the study period and varied considerably between hospitals. Important factors such as ROP severity could not be included in the study’s scoring, and matching for overall clinical status including respiratory baseline was limited by the available data. However, an increased risk of pulmonary hypertension after anti-VEGF therapy is physiologically plausible, as lower systemic VEGF levels could impair pulmonary angiogenesis. This mechanism and the study results raise concern for systemic side effects of anti-VEGF therapy for ROP and warrant further study, ideally by randomized trial.

Click to read the study in JAMA Ophthalmology

Click to read an accompanying editorial in JAMA Ophthalmology

RELATED REPORTS

Drying prior to plastic wrapping may not provide thermoregulatory benefits in infants admitted to the neonatal intensive care unit

2 Minute Medicine Rewind April 6, 2026

Relevant Reading: Retinopathy of prematurity: A review of epidemiology and current treatment strategies

FDA approvedFor hypertension: Baxfendy (baxdrostat), May 15, 2026→

In-Depth [retrospective cohort]: Infants born between 23 and 32 weeks gestation who were diagnosed with ROP and treated with either anti-VEGF agents — bevacizumab, ranibizumab, or aflibercept — or laser at 48 neonatal intensive care units between 2010 and 2020 were included. Patients who received both anti-VEGF and laser were excluded. PH treatment was defined as initiation of a pulmonary vasodilator 7 days or more after ROP therapy; 107 (6.3%) were treated for PH. Propensity scoring was based on gestational age at birth and at ROP treatment, sex, birth weight, race, insurance type, and maximal respiratory therapy two days before ROP treatment. An echocardiogram risk score reflecting the likelihood of echo based on hospital site and year was also included in the scoring. In the propensity score-matched cohort, 7.7% of infants receiving anti-VEGF and 4.7% of infants receiving laser were treated for PH for an odds ratio of 1.71 [95% confidence interval (CI) 1.00-2.95, p=0.047]. After adjustment for hospital and year, the odds ratio was 1.62 and 95% CI was 0.90-2.89 (p=0.10).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adverse drug effectsneonatal intensive care unit (NICU)premature infantspulmonary hypertensionretinopathyretinopathy of prematurity (ROP)VEGF
Previous Post

Fine needle biopsy remains a reliable test for thyroid cancer diagnosis

Next Post

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

RelatedReports

Newborn intensive care collage: an open infant warming bed with an overhead heater, a striped flannel blanket and a pacifier
Emergency

Drying prior to plastic wrapping may not provide thermoregulatory benefits in infants admitted to the neonatal intensive care unit

April 10, 2026
Newborn intensive care collage: an open infant warming bed with an overhead heater, a striped flannel blanket and a pacifier
Weekly Rewinds

2 Minute Medicine Rewind April 6, 2026

April 6, 2026
#VisualAbstract: Riociguat Improves Exercise Following Balloon Pulmonary Angioplasty in Patients with Pulmonary Hypertension
StudyGraphics

#VisualAbstract: Riociguat Improves Exercise Following Balloon Pulmonary Angioplasty in Patients with Pulmonary Hypertension

August 15, 2025
Migraine collage: a woman with her eyes closed and soft arcs radiating from her temple, a glass of water and a sleep mask
Neurology

Patient values and preferences when treating acute episodic migraine

March 26, 2025
Next Post

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Scoop thrombectomy safe and effective as a novel technique for treating thrombosed arteriovenous fistulas

#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.